Kolexia
Cambier Nathalie Hématologie
Cambier Nathalie
Hématologie
Hôpital Huriez
Lille, France
81 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Polyglobulie Polyglobulie primitive essentielle Thrombocytémie essentielle Leucémies Thrombocytose Myélofibrose primitive Leucémie aigüe myéloïde Anémie Leucémie myélomonocytaire chronique

Collaborateurs

Voir plus
Kiladjian Jean-Jacques
Kiladjian Jean-Jacques
Hôpital Saint-Louis, Paris, France
Plantier-Colcher Isabelle
Plantier-Colcher Isabelle
Centre Hospitalier de Roubaix, Roubaix, France
Preudhomme Claude
Preudhomme Claude
Hôpital Albert Calmette, Lille, France
Marolleau Jean Pierre
Marolleau Jean Pierre
Centre Hospitalier D'Amiens Salouël Site Sud, Salouël, France

Industries

Voir plus
Pfizer
2 collaboration(s)
Dernière en 2021
Abbvie
1 collaboration(s)
Dernière en 2020
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Interleukin 10 (IL10) and IL15 Significantly Decreased in Chronic Myeloid Leukemia Patients Presenting with Tyrosine Kinase Inhibitor (TKI) Withdrawal Syndrome (TWS). Results from the Prospective, Explorative and Multicenter « Kiwis » Study Designed for TWS. Clinicaltrial.Gov ID: NCT03996096; Study Number: 18-206
65th ASH Annual Meeting Abstracts   02 novembre 2023
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM): A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy
Essai Clinique (GSK)   30 octobre 2023
Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease.
Kidney international reports   07 septembre 2023
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
Blood advances   17 juillet 2023
Extended Access of Momelotinib in Adults With Myelofibrosis: Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Essai Clinique (GSK)   16 juin 2023
#2664 CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS WITH LYSOZYME NEPHROPATHY AND CMML RENAL INFILTRATION DISPLAY MARKERS OF SEVERE DISEASE
60th ERA Congress, 15-18 June 2023: Congress Abstracts   14 juin 2023
Atteintes rénales au cours de la leucémie myélomonocytaire chronique : néphropathie au lysozyme et infiltration rénale par la LMMC, marqueurs de mauvais pronostic
86e CONGRÈS FRANÇAIS DE MÉDECINE INTERNE   01 juin 2023
Simplify 1: A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Essai Clinique (GSK)   10 mai 2023
Simplify 2: A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib
Essai Clinique (GSK)   10 mai 2023
Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)
Annual Meeting Abstracts 2022   15 novembre 2022